ライフサイエンスコーパス: hospital stay

1 ncardiac surgery (requiring at least a 2-day hospital stay).

2 practice (0.74% for office visits; 0.51% for hospital stays).

3 as time to functional recovery and length of hospital stay.

4 smoking cessation interventions during their hospital stay.

5 according to the presence of AF during index hospital stay.

6 lure at 180 days, or the length of the index hospital stay.

7 , length of Intensive Care Unit, and overall hospital stay.

8 ssociated with clinical failure or length of hospital stay.

9 in the majority of COVID-19 patients during hospital stay.

10 ing higher mortality and prolonged length of hospital stay.

11 erapy during ICU stay, and length of ICU and hospital stay.

12 ificant effect on survival, length of ICU or hospital stay.

13 r 30-day readmissions or prolonged length of hospital stay.

14 with patients with newly detected AF during hospital stay.

15 ion, 30-day readmission, operative time, and hospital stay.

16 of hypoxemic adjuvant therapies, and ICU and hospital stay.

17 bidity, length of critical care, and overall hospital stay.

18 ty and mortality, and shortens the length of hospital stay.

19 ge, 238 (55%) acquired carriage during their hospital stay.

20 es, antimicrobial stewardship, and length of hospital stay.

21 pendent risk factor for mortality and longer hospital stay.

22 as associated with longer duration of MV and hospital stay.

23 ion of mechanical ventilation, and length of hospital stay.

24 moderate pancreatitis, may reduce length of hospital stay.

25 ous ammonia, time of recovery, and length of hospital stay.

26 gastrointestinal symptoms and the length of hospital stay.

27 ore meals (the basal-bolus group) during the hospital stay.

28 ratio, 0.62; 95% CI, .29-1.36) nor length of hospital stay.

29 sk of pulmonary embolism and required longer hospital stay.

30 MDROs on morbidity, mortality, and length of hospital stay.

31 nd postoperative complications and a shorter hospital stay.

32 MIE was associated with a shorter hospital stay.

33 , 1.74; 95% CI, 1.42 to 2.14), and length of hospital stay.

34 er TURP, including reduced complications and hospital stay.

35 educed pulmonary complications and length of hospital stay.

36 wer for the mean time to full feeds and mean hospital stay.

37 tion, length of intensive care unit stay and hospital stay.

38 AT-DILI, but significantly reduced length of hospital stay.

39 , initiation of ventilation, and duration of hospital stay.

40 Dindo grade > 1 complications, and length of hospital stay.

41 e care unit, and 30 patients died during the hospital stay.

42 ostoperative 90-day mortality, and length of hospital stay.

43 or be readmitted, they also had the longest hospital stays.

44 rt, and longer intensive care unit (ICU) and hospital stays.

45 n survivors was also associated with shorter hospital stays.

46 nd intensive care unit admission and shorter hospital stays.

47 rbid function, death, and prolonged ICU- and hospital stays.

48 ; 95% CI, 0.37-0.80), but prolonged ICU- and hospital stays.

49 determine predictors of mortality and longer hospital stays.

50 odds ratio [aOR], 1.97; P = .01) and longer hospital stay (1.34; P < .001).

51 [n/N = 7/296] vs 33.5% [n/N = 779/2322]) and hospital stays (1.7% [n/N = 5/296] vs 24.2% [n/N = 561/2

52 t stay (151 vs 117 hours; P < .001), but not hospital stay (11 vs 12 days; P = .50), was longer in th

53 ther outcomes demonstrated shorter length of hospital stay (11 vs 13 days, P = 0.03), less likelihood

54 AA had more prolonged length of hospital stays (11.1 +/- 13.4 days vs 7.7 +/- 23 days) t

55 43 [2.8%]; P < .001) and prolonged length of hospital stay (12 vs 8 days; P = .04).

56 ration (16.6% vs 21.0%; P = 0.22), length of hospital stay (12.2 vs 12.2; P = 0.99) and rate of stoma

57 er ICU (median, 4.8 vs 1.8 d; p < 0.001) and hospital stay (16.0 vs 8.16 d; p < 0.001), greater requi

58 Recipients with complications had longer hospital stay (17 versus 9 d; P = 0.001) than those with

59 The overall hospital stay (2.8 days vs. 4.1 days, p < 0.0001) and co

60 peratively were more likely to have a longer hospital stay (2.9 d vs. 2.5 d, P <0.001) and were more

61 Ambulatory Medical Care Surveys) and 108472 hospital stays (2010 National Hospital Discharge Survey)

62 ys vs. 28 days), as was the median length of hospital stay (21 days vs. 33 days) (P<0.001 for both co

63 e was associated with an increased length of hospital stay (3.7 days, 95% CI 0.3-6.9), increased prob

64 r mortality (17.5% vs 9.8%; P<0.001), longer hospital stay [3 (1-7) vs 2 (1-5) days; P = 0.021], and

65 nned reoperations (4.4% vs 1.3%), and longer hospital stay (30.4% vs 6.2% >=3 days (all P < 0.01).

66 ct of SMI on inpatient admissions, length of hospital stay, 30-day hospital readmission rates, and em

67 hemical parameters at POD 3 of 7, as well as hospital stay, 30-day mortality were similar in recipien

68 pressed as cycle threshold values; length of hospital stay; 30-day mortality; and whether the InfA in

69 positive group; P = .004), and a shorter in-hospital stay (34 days [IQR 18-55] vs 51 days [IQR 35-91

70 cy Unit (2 vs. 6 days, P = 0.001), and total hospital stay (5 vs. 8 days, P = 0.001) were observed af

71 duration of ventilation, duration of ICU and hospital stay, 6-month recurrence, and rehospitalization

72 [95% CI, -26.3% to 23.7%]), median length of hospital stay (8 d in both groups; adjusted difference,

73 ; p = 0.036), as well as a shorter length of hospital stay (8.9 vs. 12.5 days; p = 0.015).

74 (60-400) vs 300 mL (150-500), P = 0.001] and hospital stay [8 (6-12) vs 9 (7-14) days, P < 0.001] wer

75 Twelve percent (n = 333) died during their hospital stay, 8.1% (n = 222) of patients died postdisch

76 ission, and discharge destination) and cost (hospital stay, 90-, 180-, and 365-d) after adjusting for

77 aximum SCAI stage (B-E) reached during their hospital stay according to drug and device utilization.

78 .70; 95% CI, 2.27-3.22; P < .001) and longer hospital stay (adjusted multiplicative difference, 2.14;

79 of the primary outcome, durations of ICU and hospital stay, adverse events, and all-cause mortality a

80 espectively, interstage interval: <=16 days, hospital stay after ALPPS stage 2: <=10 days, rates of o

81 mortality, readmission to ICU, and length of hospital stay after ICU discharge.Methods: Data were acc

82 21% after LDP, or an average 2.3 days longer hospital stay after LDP than after ODP.

83 The median length of hospital stay after onset was 8 days in the linezolid gr

84 sed on a decrease of infection and length of hospital stay after surgery.

85 tion, and length of intensive care and total hospital stay, although the lack of randomized, controll

86 apenem resistance on mortality and length of hospital stay among inpatients in LMICs with a bloodstre

87 Outcomes were defined as rates of IHC during hospital stay among patients with non-OAC-ICH, VKA-ICH a

88 The patients in the SSI group had a longer hospital stay and a higher rate of delayed gastric empty

89 with increased morbidity including length of hospital stay and an increased incidence of resistant in

90 ipated laser benefits for ThuVARP of reduced hospital stay and complications were not observed.

91 intestinal events, and reduces the length of hospital stay and costs.

92 placing them at increased risk of prolonged hospital stay and death.

93 sion (LTP), postoperative complications, and hospital stay and fee between the two groups.

94 ic ulcer bleeding, and the shorter length of hospital stay and fewer complications outweigh a higher

95 OM was defined as death occurring during the hospital stay and FTR as POM rate among patients with ma

96 Tc17, and Th17 were associated with shorter hospital stay and may play a protective role, whereas Tc

97 approach in terms of length of postoperative hospital stay and morbidity.

98 tance is associated with increased length of hospital stay and mortality in patients with bloodstream

99 scopic lobectomy was associated with shorter hospital stay and no significant difference in long-term

100 d robotic approach synergistically decreases hospital stay and overall cost compared with other strat

101 duction of enteral feeds to be beneficial to hospital stay and patient outcomes.

102 ctal cancer is linked to a shorter length of hospital stay and reduced postoperative mortality.

103 The hospital stay and time to the first meal were shorter in

104 The patient had an uneventful postoperative hospital stay and was asymptomatic on a follow-up five m

105 CIIN is associated with longer hospital stays and changes in immunosuppressive treatmen

106 o be discharged home and necessitated longer hospital stays and greater hospitalization charges.

107 by increasing hospital mortality, extending hospital stays and increasing frequency of readmissions.

108 first rank to reduce SSI, pneumonia, sepsis, hospital stay, and antibiotic use.

109 fectious complications, mortality, length of hospital stay, and any treatment-related adverse events.

110 impacted patient care, management, length of hospital stay, and efficient use of hospital resources.

111 endency and increases morbidity, duration of hospital stay, and health care costs.

112 nical ventilation, intensive care unit stay, hospital stay, and highest primary graft dysfunction sco

113 ortality, unscheduled readmission, length of hospital stay, and kidney impairment.

114 easures included 30-day morbidity, length of hospital stay, and length of intensive care unit stay.

115 mission assessment, minimum follow-up during hospital stay, and minimum of two in-hospital outcomes w

116 cations, severity of complication, length of hospital stay, and mortality were considered as outcome

117 d findings, injury severity score, length of hospital stay, and number of mortalities.

118 ention (TVI) on post-operative TR, length of hospital stay, and on a composite endpoint consisting of

119 icated appendicitis, postoperative length of hospital stay, and overall duration of postoperative ant

120 sing a 100 mm visual analog scale, length of hospital stay, and patient-reported quality of life.

121 nd mortality, rate of reoperation, length of hospital stay, and rate of stoma closure at 6 months.

122 ra-abdominal abscess, reoperation, length of hospital stay, and readmission.

123 izations, ICU/intubation requirement, longer hospital stays, and >4-fold increase in mortality compar

124 ource utilization: emergency room visits and hospital stays, and (4) total annual and out-of-pocket h

125 urgery, durations of intensive care unit and hospital stays, and all-cause mortality at postoperative

126 of mechanical ventilation, length of ICU and hospital stays, and doses of sedative and analgesic drug

127 morbidity, prolonged intensive care unit and hospital stays, and even mortality before an operation w

128 R, 1.20; 95% CI, 1.03 to 1.38), and a longer hospital stay (aOR, 1.01 per day; 95% CI, 1.00 to 1.01).

129 the ISS, age, injury pattern, and length of hospital stay are predictive of both risks, enabling mon

130 We used hospitalization and duration of hospital stay as proxies for severity.

131 primary outcome was postoperative length of hospital stay assessed at time of discharge in the modif

132 lity (aOR 2.67; 95% CI 1.35-5.29) and longer hospital stay (beta + 4.13; P<0.001), while White race w

133 stically significant difference in length of hospital stay between children receiving beta-lactam mon

134 ere found in major morbidity, mortality, and hospital stay between MIPD and OPD.

135 ation increased out-of-bed activities during hospital stay but did not improve outcomes.

136 protocols have resulted in shorter length of hospital stay by 30% to 50% and similar reductions in co

137 ) 1.02 (1.93) ; P > .9), or median length of hospital stay (CACPR: 8 days, non-CACPR: 9 days; P = .6)

138 During the hospital stay, caloric goals were reached in 800 (79%) a

139 Enteric fever can lead to prolonged hospital stays, clinical complications, and death.

140 s and hospitalized patients only and shorter hospital stay (coefficient = -2.02, -2.61, and -2.18; P

141 ore cost-effective and resulted in a shorter hospital stay compared to two sessions.

142 e hospitalized and had significantly shorter hospital stays compared with infants born to unvaccinate

143 he percentages of office visit conditions or hospital stay conditions seen were less than the applica

144 implementation costs and length and cost of hospital stay, costs of warming blanket use, blood trans

145 randomized clinical trial on complications, hospital stay, costs, quality of life, and survival is h

146 Cost-effectiveness based on complications, hospital stay, costs, quality of life, and survival was

147 The median hospital stay declined over the years for both procedure

148 Risk-adjusted mean hospital stay decreased by 8.6%, representing nearly 100

149 n patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% confidence in

150 Length of hospital stay did not differ significantly after the pol

151 easures included 1) One-year total length of hospital stay due to biliary causes following an index e

152 erence was seen in the operative time, total hospital stay, flap loss, re-exploration rates, plate ex

153 ignificantly lower than predicted throughout hospital stay for all gestation groups when compared wit

154 omparable complication rate during the index hospital stay for DCD and DBD LT, but the CCI increases

155 The postoperative length of hospital stay for open surgery group was on average 1.3

156 The mean hospital stay for the moderate group was 12.4 days vs 10

157 Hospital stays for DUA-IE were longer (median, 27 vs. 17

158 n in practice during either office visits or hospital stays for each of 186 condition categories (eg,

159 ommend the use of nutritional support during hospital stays for medical patients (patients not critic

160 e survival discharge rates and the length of hospital stay from cardiac arrest to discharge, stratifi

161 ars, male sex, BMI >/=50 kg/m, postoperative hospital stay >/=3 days, and operative time >/=3 hours.

162 5-2.66), a 27% increase in odds of length of hospital stay >2 days (95% CI 1.10-1.47), a 54% increase

163 hospital mortality, organ failure, prolonged hospital stay (>75th percentile), and unplanned readmiss

164 proportion of hospitalizations and prolonged hospital stays highlight illness severity and the need f

165 g enrolled as early as possible during their hospital stay if they are 18 years or older, admitted wi

166 ndividualised nutritional support during the hospital stay improved important clinical outcomes, incl

167 cessary antibiotic use, shortening length of hospital stay, improving influenza detection and treatme

168 bust reduction in morbidity and length of in-hospital stay in a stepped wedge cluster randomized cont

169 The duration of hospital stay in days was shorter in the SC in compariso

170 ment with NTZ did not reduce the duration of hospital stay in severe influenza-like illness.

171 andomized trials showed significantly longer hospital stay in the antibiotic treatment group (RR 0.3

172 Secondary endpoints included length of hospital stay, in-hospital mortality and adverse events.

173 The primary outcome was total length of hospital stay including re-admission up to 30 days after

174 er failure (LF) is associated with prolonged hospital stay, increased cost and substantial mortality.

175 major surgery and is associated with longer hospital stays, increased hospital costs, and 1-year mor

176 To prevent prolonged hospital stay, initiatives should in addition focus on d

177 transplantation-related mortality; length of hospital stay; intensive care unit admissions; acute gra

178 ading to clinical treatment failure, lengthy hospital stay, intravenous therapy and accretion of bact

179 The median hospital stay length was 8 days in the ND arm and 7 days

180 Other outcomes were hospital stay length, neck and shoulder morbidity, and n

181 h below 34 weeks of gestation (3.9 fold) and hospital stay longer than 5 days (5.8 fold) than control

182 patients with confirmed fractures) required hospital stays longer than 2 days; the other four patien

183 We compared the (1) length of hospital stay (LOS) and (2) duration of oxygen supplemen

184 + RPD, ERAS + OPD, ERAS + RPD) on length of hospital stay (LOS) and overall cost.

185 ial function, fitted to historical length of hospital stay (LOS) data, was used to project future LOS

186 S is needed, along with control of length of hospital stay (LOS) following CS.

187 well nutritional variables predict length of hospital stay (LOS) in patients receiving ERAS protocols

188 aseline clinical details, outcome, length of hospital stay (LOS), and costs.

189 avien-Dindo >=3 complications, and length of hospital stay (LOS).

190 ric intensive care unit (PICU) and length of hospital stay (LOS).

191 Primary endpoint was length of hospital stay (LOS).

192 antibiotic therapy, and outcomes (length of hospital stay [LOS] and in-hospital mortality).

193 uries (AIS >/= 3), death within 72 hours, or hospital stay <48 hours were excluded.

194 9), reoperation (11% vs 13%, P = 0.329), and hospital stay (mean 17 vs 17 days, P > 0.99) were compar

195 .90), sepsis (RR = 0.09; 95% CI, 0.01-0.94), hospital stay (mean = 9.66 days, 95% CI, 7.60-11.72), an

196 ratio, 5.5; 95% CI, 2.4-13.0), have a longer hospital stay (mean difference, 16.1 d; 95% CI, 8.4-23.7

197 e, -12 hours; 95% CI, -21 to 2; P=0.09), and hospital stay (median, 14 days and 14 days, respectively

198 These patients also experienced reduced hospital stay (median: 8 days vs 9 days, P = 0.001).

199 rdion grade >/=3, 23.05% vs 23.7%; P > .99), hospital stay (median: 8 vs 8.5 days; P = .31), 30-day r

200 It can increase the hospital stay, morbidity in postoperative period and thu

201 sion, and the lack of superior outcomes (ie, hospital stay, morbidity) could indicate that more exper

202 t within 8 weeks (150.56 [73.11 to 310.06]), hospital stay more than 3 days before sampling (2.34 [1.

203 has major public health implications-longer hospital stay, more frequent hospital admissions, greate

204 -assisted pneumonia, median ICU stay, median hospital stay, mortality rates, and ICU and hospital cos

205 To compare length of hospital stay, mortality, and readmission in adults hosp

206 Later diagnosis was associated with longer hospital stays (n = 145; R = +0.191; P < .05) and greate

207 aimed to assess mortality rate, duration of hospital stay, need for mechanical ventilation (MV), vir

208 rgical complications, no prolonged length of hospital stay, no readmission <= 90 days after discharge

209 .2; P = .03) and is associated with a longer hospital stay (odds ratio = 0.92; P < .001).

210 o, 10.4; 95% CI, 5.9-18.1), suffer prolonged hospital stay (odds ratio, 4.4; 95% CI, 3.0-6.4), and di

211 years (OR = 1.2, 95% CI; 1.1-1.3), length of hospital stay of >7 days (OR = 1.1, 95% CI; 1.02-1.2), m

212 mission with a median preoperative length of hospital stay of 29 days (25% required preoperative crit

213 ]; Pakistan, 48% [1054/2206]), with a median hospital stay of 5 days (IQR, 3-7).

214 chological events, he was discharged after a hospital stay of almost 1 year.

215 uration of more than 2 h, and an anticipated hospital stay of at least 2 days.

216 A hospital stay of less than 48 hours for routine supporti

217 ving in institutionalised care, or who had a hospital stay of more than 1 week before the surgical co

218 e >=3 points) and with an expected length of hospital stay of more than 4 days from eight Swiss hospi

219 compared the efficacy, safety, and length of hospital stay of patients receiving SPT and those where

220 kidney function, an angio-CT during the same hospital stay of the primary stent-graft procedures was

221 Hospital stays of all donors were 6 days and median sick

222 For concordance between questions and hospital stays only, 1456 questions (42.07%; 95% CI, 40.

223 he likelihood of a doctor visit or overnight hospital stay or health status as reported by the respon

224 30% respectively, P = 0.344), complications, hospital stay or mortality rate were observed.

225 independently associated with the length of hospital stay (OR: 2.17; 95% CI: 1.45, 3.26; P < 0.001).

226 CI, 2.12 to 9.29; P < .001) and have shorter hospital stays (OR, 0.84; 95% CI, 0.77 to 0.91; P < .001

227 .08; 95% CI, 3.46 to 7.45; P < .001), longer hospital stays (OR, 1.15; 95% CI, 1.11 to 1.20; P < .001

228 tion (but not NPA) correlated with length of hospital stay (P = .04) and requirement for mechanical v

229 s severe complications (P < 0.001), 25% less hospital stay (P = 0.013), and 65% less ICU stay (P < 0.

230 culture positivity (P = 0.040) and a shorter hospital stay (P = 0.035).

231 The length of hospital stay (P for trend = 0.002) was longer, and all-

232 0.89; p=0.0250), and 1-day shorter length of hospital stay (p=0.0091).

233 the greatest independent impact on prolonged hospital stay [PAF 27.6% (95% CI 23.5-31.8)].

234 bations, ICU readmissions, prolonged ICU and hospital stay, persistent cognitive problems, and higher

235 obstacles for achieving TO were a prolonged hospital stay, postoperative complications, and readmiss

236 nisolone significantly reduces the length of hospital stay, postoperative serum bilirubin and PT-INR,

237 We collected demographics, mortality, hospital stay, prior medical history, comorbidities, rea

238 deficits was associated with posttransplant hospital stay (r = 0.34, P = 0.04), but not with delisti

239 including maternal weight gain, duration of hospital stay, readmission rate, nausea and vomiting sym

240 tage liver disease score >=40, postoperative hospital stays, rejection, and nonanastomotic biliary st

241 Prolonged length of hospital stay represented the major obstacle to achieve

242 he results of the screening tools, length of hospital stay, serum albumin and cholesterol concentrati

243 ; 95% CI, -0.43 to -0.13 d; p = 0.0003), and hospital stay (standardized mean difference, -0.30 d; 95

244 Thoracoscopy produce shorter hospital stay [standardized mean differences (SMD) -11.9

245 Most VTEs occur after hospital stay; still a few patients receive extended pha

246 duration of treatment and shorter length of hospital stay than treatment with oral morphine, with si

247 requiring intensive care support and longer hospital stays, than those with mono-infection (median 2

248 l [CI] 1.21-2.80, p = 0.005, I2 = 100%), had hospital stays that were increased by 0.59 days (pooled

249 ndary clinical end points were the length of hospital stay, the percentage of infants who required su

250 lustering analysis using data from patients' hospital stays to retrospectively identify patient subgr

251 including increased healthcare costs, longer hospital stays, unnecessary consultations, and inappropr

252 Secondary outcomes were length of ICU and hospital stay; ventilator-free days through day 28; pneu

253 Median (IQR) ICU and hospital stay was 0 (0-2) and 12 (9-18) days, respective

254 The mean length of hospital stay was 0.9 days longer in the control group.

255 appendectomy (98% laparoscopic), and median hospital stay was 1 (1-2) day.

256 The median hospital stay was 1 to 9 days across specialties.Postope

257 Median length of hospital stay was 1.5 days.

258 Median hospital stay was 12 days (IQR 9-18) and 40 patients wer

259 Median length of hospital stay was 15 days (IQR = 9-25).

260 The median hospital stay was 15 days (range: 3-236).

261 Median length of hospital stay was 15 days in the standard TTS arm and 17

262 The median length of hospital stay was 17.5 days.

263 e cohort, femoral access increased to 95.3%, hospital stay was 2 days, and 90.3% were discharged home

264 Median hospital stay was 3.0 days, and the overall major advers

265 nts were uneventful and the median length of hospital stay was 3.1 days (range 1-14 days).

266 Mean hospital stay was 48 h in both study groups.

267 The length of hospital stay was 5 days in the EOR group and 8 days in

268 The median length of hospital stay was 6 days.

269 The mean length of hospital stay was 6.4+/-7.3 days with a mean+/-SD cost o

270 Length of hospital stay was 8 versus 10 days (P < 0.001), respecti

271 The average hospital stay was 8.7 +/- 13.9 days, and the total cost

272 Hospital stay was longer after open surgery compared wit

273 The length of hospital stay was longer in conv-LRYGB.

274 d in lower blood use; however, the length of hospital stay was longer, and this strategy required cli

275 Length of hospital stay was prolonged (5.04 d relative effect, 95%

276 duction of FilmArray GI panel, but length of hospital stay was shorter (3 vs. 7.5 days, p = 0.0002) f

277 Median hospital stay was shorter after MIE (14 vs 13 days, P =

278 Overall, hospital stay was shorter after MIG compared with OG (8

279 The median length of hospital stay was shorter in the TAE group-8 versus 16 d

280 Hospital stay was significantly reduced by 2.8 days in i

281 Postoperative hospital stay was significantly shorter for patients in

282 P < 0.0001, I = 16%, n = 1387] and length of hospital stay (weighted mean difference -1.57 days, 95%

283 days (5.0-14.0 d); and durations of PICU and hospital stay were 9.4 days (5.6-15.4 d) and 15.7 days (

284 Median operative time and length of in-hospital stay were 95 minutes (range 45-232 minutes) and

285 Duration of ventilation, ICU stay, and hospital stay were all significantly longer among acute

286 Failure at end of treatment and length of hospital stay were also analyzed.

287 Morbidity, mortality, and hospital stay were evaluated.

288 received early ID intervention during their hospital stay were less likely to be readmitted after di

289 Venous ammonia at day 5 and length of hospital stay were significantly lower in the LOLA group

290 postoperative morbidity (Dindo-Clavien >3b), hospital stay were similar in both groups.

291 Significantly longer hospital stays were seen in cases aged 0- 4 weeks (media

292 Intensive care and hospital stays were significantly more prolonged in the

293 h excellent oncologic outcomes and decreased hospital stay when compared to the open approach.

294 METHODS/Ninety-one patients died during the hospital stay while 92 patients from the 493 individuals

295 iagnosis by POCT was associated with shorter hospital stay, while old age, diabetes, cancer, use of a

296 diac transplantation and prolonged length of hospital stay with the purpose of assisting clinicians a

297 f prolonged postoperative ileus, and shorter hospital stays with fewer readmissions.

298 of camels, poor hand hygiene, and overnight hospital stays with respiratory complaints.

299 ociated with significantly shorter length of hospital stay without an increase in the risk of adverse

300 .75], p < 0.00001) and shorter postoperative hospital stay (WMD: -2.36 [-3.06 to -1.66] d, p < 0.0000